Daphne A. Haas-Kogan, MD

Harvard University Cambridge, MA, A.B., 1986, Biochemical Sciences
University of California, San Francisco, M.D., 1991, Medicine
University of California, San Francisco, Postdoctorate, 1993, Radiation Oncology
University of California, San Francisco, Residency, 1997, Radiation Oncology

• 1989-1990
  Research Fellow, Laboratory of Dr. J. Michael Bishop, G. W. Hooper Foundation, University of California, San Francisco, CA
• 1991-1992
  Medical Intern, California Pacific Medical Center, San Francisco, CA
• 1992-1994
  Postdoctoral Fellow, Laboratory of Dr. Mark Israel, Brain Tumor Research Institute, University of California, San Francisco, CA
• 1994-1997
  Resident, Department of Radiation Oncology, University of California, San Francisco, CA.
• 1996-1997
  Chief Resident, Department of Radiation Oncology, University of California, San Francisco, CA
• 1997-2003
  Assistant Professor, Dept. of Radiation Oncology, University of California, San Francisco, CA
• 2002-2011
  Associate Professor, Dept. of Radiation Oncology, University of California, San Francisco, CA
• 2003-present
  Vice-Chair for Research, Dept. of Radiation Oncology, University of California, San Francisco, CA
• 2011-present
  Professor, Dept. of Radiation Oncology, University of California, San Francisco, CA

• 1985
  Joseph L. Barrett Award for Teaching, Harvard University
• 1986
  Phi Beta Kappa, Harvard University
• 1986
  Thomas T. Hoopes Prize awarded to Senior Honors Thesis
• 1986
  Summa cum laude awarded to Senior Honors Thesis
• 1991
  Alpha Omega Alpha, University of California, San Francisco
• 1995
  ASTRO Basic Scientist Research Award
• 1995
  Junior Scientist Travel Award, 10th International Congress of Radiation Research
• 1995
  American Cancer Society Clinical Oncology Fellowship
• 1997
  Radiological Society of North America Scholar Award
• 1998
  UCSF Dean representative to Association of American Medical Colleges Professional Development Seminar for Junior Women Faculty, Santa Fe, New Mexico.
• 1999
  Pfizer Scholars Grant for New Faculty.
• 1999
  First place: CAP competition, General Clinical Research Center National Meeting; Arlington, VA.
• 1999
  UCSF-Mount Zion Clinical Investigator Award.
• 2000
  American Society of Clinical Oncology Career Development Award.
• 2002
  Henry J. Kaiser Award for Excellence in Teaching, UCSF School of Medicine.
• 2002
  UCSF Nominee, Assoc of American Medical Colleges (AAMC) Humanism in Medicine Award.
• 2003
  Nominated for Teaching Award, UCSF School of Medicine.
• 2004
  Nominee: Henry J. Kaiser Award for Excellence in Teaching, UCSF School of Medicine.
• 2005
  Selected one of Best San Francisco Doctors for San Francisco Magazine, January 2005.
• 2006
  Alpha Omega Alpha, nominated by Medical Student Class of 2007 for AOA membership in the alumni category at the University of California, San Francisco.
• 2009-2010
  Mentor: Howard Hughes Medical Institute Research Training Fellowship for Medical Students.
• 2007-2011
  Best Doctors in America®

• Ward CS, Venkatesh HS, Brandes AH, Van Criekinge1 M, Chaumeil MM, Dafni H, Kurhanewicz J, James CD, Haas-Kogan DA, and Ronen SM. Noninvasive detection of target modulation following phosphatidylinositol-3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy, Can Res. 2010, 70(4):1296-1305. Epub 2010 Feb 9.
• Fan QW, Cheng CK, Hackett C, Feldman M, Houseman BT, Haas-Kogan DA, Nicolaides T, James, CD, Debnath J, Shokat KM, and Weiss WA. Akt and autophagy cooperate to promote survival in glioma. Science Signaling, 2010, 9;3(147):ra81.
• Chen CP and Haas-Kogan DA. Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Expert Rev Mol Diagn. 2010, 10(7):883-95.
• Prados MD and Haas-Kogan DA. Low-grade Glioma: Potential New Markers and Strategies. Neuro-Oncology, 2011, in press; (PMC Journal - In Process).
• Mishra KK, Squire S, Lamborn K, Banerjee A, Gupta N, Wara WM, Prados MD, Berger MS, Haas-Kogan DA. Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. J Neuro-Oncology, 2010 Mar 11. [Epub ahead of print]. PMCID: PMC2951507
• Haas-Kogan DA, Banerjee A, Poussaint TY, Kocak M, Prados MD, Geyer JR, Fouladi M, Broniscer A, Minturn JE, Pollack IF, Packer RJ, Boyett JM, and Kun LE. Phase II Trial of Tipifarnib and Radiation in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas. Neuro-Oncology, 2011, 13(3):298-306.
• Prabhu S, Ng S, Vajapeyam S, Pollack IF, Geyer R, Haas-Kogan DA, Boyett J, Kun L, and MD, Poussaint TY. DTI Assessment of the Brainstem White Matter Tracts in Pediatric BSG Before and After Therapy. Childs Nervous System, 2011, 27:11–18.
• More SS, Itsara M, Yang X, Geier EG, Tadano MK, Seo Y, VanBrocklin H, Weiss WA, Sabine M, Haas-Kogan DA, DuBois SG, and Matthay KK and Giacomini KM. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clinical Cancer Research. 2011, 17(8):2339-49.
• Poussaint TY, Kocak M, Vajapeyam S, Packer RI, Robertson RL, Geyer R, Haas-Kogan DA, Pollack IF, Vezina G, Zimmerman R, Cha S, Patay Z, Boyett JM, and Kun LE. MR Imaging as a Central Component of Clinical Trials Analysis in Brainstem Glioma: A Report from the Pediatric Brain Tumor Consortium (PBTC). Neuro-Oncology, 2011 Apr;13(4):417-27. Epub 2011 Feb 4. PMID: 21297126
• Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley MY, Weiss WA, Matthay KK, Davidoff AM, DuBois SG, and Haas-Kogan DA. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Letters. 2011, 306(2):223-9.
• Prasad G, Sottero T, yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger M, Aftab DT, Prados MD, Haas-Kogan DA. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro-Oncology, 2011 Apr;13(4):384-92. Epub 2011 Feb 11. PMID: 21317208 Zheng S, Houseman EA, Morrison Z, Wrensch MR, Patoka JS, Ramos C, Haas-Kogan DA, McBride S, Marsit CJ, Christensen BC, Nelson HH, Stokoe D, Wiemels JL, Chang SM, Prados MD, Tihan T, Vandenberg SR, Kelsey KT, Berger MS, Wiencke JK. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro-Oncology, 2011, 13(3):280-9.
• Polishchuk AL, Dubois SG, Haas-Kogan DA, Hawkins R, Matthay KK. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer, 2011, 117(18):4286-93.
• Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro-Oncology, 2011, in press.
• Pejavar S, Polley MY, Rosenberg-Wohl S, Chennupati S, Prados MD, Berger MS, Banerjee A, Gupta N, and Haas-Kogan DA. Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy. J Neurooncol. 2012 Jan;106(2):367-75.